SHPH SHUTTLE PHARMACEUTICALS HOLDINGS INC Expansion Plans 8-K Filing 2024 - Clinical Trial Agreement Shuttle Pharmaceuticals Holdings, Inc. announced a $2.3 million agreement with Theradex Systems, Inc. to oversee a Phase 2 clinical trial for Ropidoxuridine in glioblastoma patients, which is set to last 53 months.Get access to all SEC 8-K filings of the SHUTTLE PHARMACEUTICALS HOLDINGS INC